RTA‑408 induces JNK‑dependent apoptosis and autophagy in breast cancer cells
Oncology Letters · 11.06.2026 · 32 (2) · 1-10
DOI: 10.3892/ol.2026.15692 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 11.06.2026. Verfasst von Yu-Jen Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, An-Nan Hospital, China Medical University, Tainan 709, Taiwan, R.O.C. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
RTA-408 is a synthetic activator of the nuclear factor erythroid 2-related factor 2 pathway with antioxidant and anti-inflammatory act2ivity, but its antitumor effects in breast cancer (BC) have not fully been defined.The present study evaluated the antiproliferative efficacy and underlying mechanisms of RTA-408 in BC cells.Estrogen receptor-positive MCF-7 and triple-negative MDA-MB-231 BC cells were exposed to 0-1,000 nM RTA-408 for 72 h in standard serum-containing culture medium.Cell viability was quantified using a tetrazolium-based colorimetric assay and apoptosis was evaluated by the Muse ® Annexin V & Dead Cell assay based on Annexin V and 7-amino-actinomycin D staining; the expression levels of JNK, p38, ERK, beclin-1, microtubule-associated protein 1 light chain 3B (LC3B), p62/sequestosome 1 (SQSTM1) and poly (ADP-ribose) polymerase (PARP) were assessed by western blotting.Pathway dependence was examined using the JNK inhibitor SP600125.Results showed that RTA-408 reduced cell viability in a concentration-dependent manner, with an IC 50 of ~400 nM, decreasing survival to 28% in MCF-7 cells and 22% in MDA-MB-231 cells at 1,000 nM.RTA-408 increased annexin V + apoptotic fractions, enhanced PARP cleavage and increased beclin-1, LC3B and p62/SQSTM1 levels.RTA-408 markedly enhanced JNK phosphorylation, with more modest activation of p38 and ERK.Pharmacological inhibition with SP600125 attenuated JNK phosphorylation, reduced apoptotic responses and diminished autophagy-associated marker accumulation, supporting the notion that JNK signaling contributes, at least in part, to these effects.These findings indicate that RTA-408 exerts nanomolar antiproliferative activity in both hormone receptor-positive and triple-negative BC cells through a JNK-dependent mechanism that simultaneously engages apoptosis and autophagy, supporting further in vivo and translational investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, An-Nan Hospital, China Medical University, Tainan 709, Taiwan, R.O.C.
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
- Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C.
- Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
- Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
- Department of Clinical Research, An-Nan Hospital, China Medical University, Tainan 709, Taiwan, R.O.C.
Zitieren
APA
Chen, Y. J., Tsai, H. P., Chen, M. Y., Chen, I. H., Chen, W. C., Tseng, T. T., Wang, C. Y., & Lee, J. H. (2026). RTA‑408 induces JNK‑dependent apoptosis and autophagy in breast cancer cells. Oncology Letters, 32(2), 1-10. https://doi.org/10.3892/ol.2026.15692
Vancouver
Chen YJ, Tsai HP, Chen MY, Chen IH, Chen WC, Tseng TT, et al. RTA‑408 induces JNK‑dependent apoptosis and autophagy in breast cancer cells. Oncology Letters. 2026;32(2):1-10. doi:10.3892/ol.2026.15692
BibTeX
@article{Chen2026,
author = {Chen, Yu-Jen and Tsai, Hung-Pei and Chen, Mei-Yin and Chen, I-Hsiang and Chen, Wei-Chieh and Tseng, Tzu-Ting and Wang, Chen-Yu and Lee, Jia-Hau},
title = {RTA‑408 induces JNK‑dependent apoptosis and autophagy in breast cancer cells},
journal = {Oncology Letters},
year = {2026},
volume = {32},
number = {2},
pages = {1--10},
doi = {10.3892/ol.2026.15692}
}
EUVIMED